Front-Line Maintenance Therapy in Advanced Ovarian Cancer-Current Advances and Perspectives

被引:11
作者
Reverdy, Thibaut [1 ,2 ]
Sajous, Christophe [1 ,2 ]
Peron, Julien [1 ,2 ]
Glehen, Olivier [3 ,4 ]
Bakrin, Naoual [3 ,4 ]
Gertych, Witold [4 ,5 ]
Lopez, Jonathan [6 ]
You, Benoit [1 ,2 ,4 ]
Freyer, Gilles [1 ,2 ,4 ]
机构
[1] Hosp Civils Lyon IC HCL, Hop Lyon Sud, Inst Cancerol, Oncol Dept, F-69310 Lyon, France
[2] Univ Lyon, F-69310 Lyon, France
[3] Ctr Hosp Lyon Sud, Dept Surg Oncol, F-69310 Lyon, France
[4] Lyon 1 Univ, EA CICLY, F-69310 Lyon, France
[5] Ctr Hosp Lyon Sud, Dept Gynecol Surg, F-69310 Lyon, France
[6] Hosp Civils Lyon, Hop Lyon Sud, Biochem & Mol Biol Dept, F-69310 Lyon, France
基金
澳大利亚研究理事会;
关键词
ovarian cancer; front-line maintenance therapy; PARP inhibitors; anti-angiogenics; immunotherapy; BRCA; 1; 2; homologous recombination deficiency; PHASE-III TRIAL; HOMOLOGOUS RECOMBINATION DEFICIENCY; ADVANCED EPITHELIAL OVARIAN; ARIEL2; PART; FALLOPIAN-TUBE; OPEN-LABEL; BEVACIZUMAB; RUCAPARIB; INHIBITORS; PACLITAXEL;
D O I
10.3390/cancers12092414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic BRCA mutations or other homologous recombination deficiencies (HRD), all involved in double strand DNA Damage Repair (DDR). Other therapeutic paradigms are currently being explored, including combinations of immune-checkpoints inhibitors, chemotherapy, bevacizumab and PARP inhibitors. In addition to these clinical advances, molecular characterization of the tumors and their correlations with drugs efficacy are needed to better understand which patient will benefit the most from the various treatments available to date.
引用
收藏
页码:1 / 18
页数:17
相关论文
共 77 条
  • [21] Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
    Gonzalez-Martin, A.
    Pothuri, B.
    Vergote, I.
    DePont Christensen, R.
    Graybill, W.
    Mirza, M. R.
    McCormick, C.
    Lorusso, D.
    Hoskins, P.
    Freyer, G.
    Baumann, K.
    Jardon, K.
    Redondo, A.
    Moore, R. G.
    Vulsteke, C.
    O'Cearbhaill, R. E.
    Lund, B.
    Backes, F.
    Barretina-Ginesta, P.
    Haggerty, A. F.
    Rubio-Perez, M. J.
    Shahin, M. S.
    Mangili, G.
    Bradley, W. H.
    Bruchim, I.
    Sun, K.
    Malinowska, I. A.
    Li, Y.
    Gupta, D.
    Monk, B. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) : 2391 - 2402
  • [22] DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
    Gupta, Rajat
    Somyajit, Kumar
    Narita, Takeo
    Maskey, Elina
    Stanlie, Andre
    Kremer, Magdalena
    Typas, Dimitris
    Lammers, Michael
    Mailand, Niels
    Nussenzweig, Andre
    Lukas, Jiri
    Choudhary, Chunaram
    [J]. CELL, 2018, 173 (04) : 972 - +
  • [23] Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer
    Harter, Philipp
    Muallem, Zelal M.
    Buhrmann, Christine
    Lorenz, Dietmar
    Kaub, Christine
    Hils, Rita
    Kommoss, Stefan
    Heitz, Florian
    Traut, Alexander
    du Bois, Andreas
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 121 (03) : 615 - 619
  • [24] Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
    Helleday, T
    Bryant, HE
    Schultz, N
    [J]. CELL CYCLE, 2005, 4 (09) : 1176 - 1178
  • [25] Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
    Hennessy, Bryan T. J.
    Timms, Kirsten M.
    Carey, Mark S.
    Gutin, Alexander
    Meyer, Larissa A.
    Flake, Darl D., II
    Abkevich, Victor
    Potter, Jennifer
    Pruss, Dmitry
    Glenn, Pat
    Li, Yang
    Li, Jie
    Gonzalez-Angulo, Ana Maria
    McCune, Karen Smith
    Markman, Maurie
    Broaddus, Russell R.
    Lanchbury, Jerry S.
    Lu, Karen H.
    Mills, Gordon B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3570 - 3576
  • [26] Hettle R, 2020, J CLIN ONCOL, V38
  • [27] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
    Hodgson, Darren R.
    Dougherty, Brian A.
    Lai, Zhongwu
    Fielding, Anitra
    Grinsted, Lynda
    Spencer, Stuart
    O'Connor, Mark J.
    Ho, Tony W.
    Robertson, Jane D.
    Lanchbury, Jerry S.
    Timms, Kirsten M.
    Gutin, Alexander
    Orr, Maria
    Jones, Helen
    Gilks, Blake
    Womack, Chris
    Gourley, Charlie
    Ledermann, Jonathan
    Barrett, J. Carl
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 1401 - 1409
  • [28] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20107, 10.3322/caac.20115, 10.3322/caac.21492]
  • [29] Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
    Johnson, Neil
    Johnson, Shawn F.
    Yao, Wei
    Li, Yu-Chen
    Choi, Young-Eun
    Bernhardy, Andrea J.
    Wang, Yifan
    Capelletti, Marzia
    Sarosiek, Kristopher A.
    Moreau, Lisa A.
    Chowdhury, Dipanjan
    Wickramanayake, Anneka
    Harrell, Maria I.
    Liu, Joyce F.
    D'Andrea, Alan D.
    Miron, Alexander
    Swisher, Elizabeth M.
    Shapiro, Geoffrey I.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (42) : 17041 - 17046
  • [30] Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
    Kaufman, Bella
    Shapira-Frommer, Ronnie
    Schmutzler, Rita K.
    Audeh, M. William
    Friedlander, Michael
    Balmana, Judith
    Mitchell, Gillian
    Fried, Georgeta
    Stemmer, Salomon M.
    Hubert, Ayala
    Rosengarten, Ora
    Steiner, Mariana
    Loman, Niklas
    Bowen, Karin
    Fielding, Anitra
    Domchek, Susan M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03) : 244 - 250